AngioDynamics 8-K: Financial Condition & Officer Pay Updates

Ticker: ANGO · Form: 8-K · Filed: Jan 5, 2024 · CIK: 1275187

Angiodynamics Inc 8-K Filing Summary
FieldDetail
CompanyAngiodynamics Inc (ANGO)
Form Type8-K
Filed DateJan 5, 2024
Risk Levelmedium
Pages4
Reading Time4 min
Key Dollar Amounts$0.01
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-condition, executive-compensation, 8-K

TL;DR

**AngioDynamics just dropped an 8-K on financial condition and officer pay, keep an eye on potential impacts.**

AI Summary

AngioDynamics, Inc. filed an 8-K on January 5, 2024, reporting events from December 29, 2023, related to its financial condition and changes in officer compensatory arrangements. This filing indicates that the company is providing an update on its operational results and potentially adjusting how certain officers are paid. For investors, this matters because changes in financial condition can directly impact stock performance, and modifications to executive compensation might signal shifts in company strategy or financial health, affecting future profitability and shareholder value.

Why It Matters

This filing provides an update on AngioDynamics' financial health and executive compensation, which can influence investor confidence and the company's operational efficiency.

Risk Assessment

Risk Level: medium — The filing mentions 'Results of Operations and Financial Condition' and 'Compensatory Arrangements of Certain Officers' without specific details, which introduces uncertainty about the nature and impact of these changes.

Analyst Insight

Investors should monitor AngioDynamics' upcoming financial disclosures for specific details on the 'Results of Operations and Financial Condition' and 'Compensatory Arrangements of Certain Officers' to understand the full impact on the company's outlook.

Key Numbers

  • 0001275187 — Central Index Key (CIK) (Unique identifier for AngioDynamics, Inc. with the SEC)
  • 20231229 — Conformed Period of Report (The date of the earliest event reported in the 8-K filing)
  • 20240105 — Filed As Of Date (The date the 8-K filing was submitted to the SEC)
  • 000-50761 — SEC File Number (The file number assigned to AngioDynamics by the SEC)
  • 11-3146460 — IRS Employer Identification No. (AngioDynamics' IRS Employer Identification Number)

Key Players & Entities

  • AngioDynamics, Inc. (company) — the registrant filing the 8-K
  • December 29, 2023 (date) — date of earliest event reported
  • January 5, 2024 (date) — date the 8-K was filed
  • NASDAQ Global Select Market (company) — exchange where AngioDynamics' common stock is traded
  • 000-50761 (dollar_amount) — Commission File Number for AngioDynamics

Forward-Looking Statements

  • AngioDynamics will provide more detailed financial results in an upcoming earnings report. (AngioDynamics, Inc.) — high confidence, target: Q1 2024
  • The changes in compensatory arrangements for officers will be further elaborated in a subsequent filing or press release. (AngioDynamics, Inc.) — medium confidence, target: Q1 2024

FAQ

What specific items are being reported in this 8-K filing by AngioDynamics, Inc.?

This 8-K filing reports on 'Results of Operations and Financial Condition', 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', 'Regulation FD Disclosure', and 'Financial Statements and Exhibits'.

What is the earliest event date reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on December 29, 2023, as stated in the 'Date of Report (Date of earliest event reported): December 29, 2023'.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on January 5, 2024, as indicated by 'FILED AS OF DATE: 20240105'.

What is the trading symbol and exchange for AngioDynamics, Inc.'s common stock?

AngioDynamics, Inc.'s common stock trades under the symbol ANGO on the NASDAQ Global Select Market, as listed under 'Securities registered pursuant to Section 12(b) of the Act'.

What is AngioDynamics, Inc.'s business address?

AngioDynamics, Inc.'s business address is 14 Plaza Drive, Latham, New York 12110, as stated in the 'BUSINESS ADDRESS' section of the filing.

Filing Stats: 1,054 words · 4 min read · ~4 pages · Grade level 13.6 · Accepted 2024-01-05 07:15:29

Key Financial Figures

  • $0.01 — ch registered Common Stock, par value $0.01 per share ANGO NASDAQ Global Select

Filing Documents

02 – Results of Operations and Financial Condition

Item 2.02 – Results of Operations and Financial Condition. On January 5, 2024, AngioDynamics, Inc. ("AngioDynamics" or the "Company") issued a press release announcing financial results for the fiscal second quarter ended November 30, 2023. A copy of the press release is furnished herewith as Exhibit 99.1. The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise shall be expressly set forth by specific reference in such a filing. Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 29, 2023, David D. Helsel, Senior Vice President of Global Operations and R&D, notified the Company of his intention to leave the Company, effective January 12, 2024, in order to pursue other opportunities. Mr. Helsel's decision to resign was not the result of any disagreement between Mr. Helsel and the Company on any matter relating to the Company's operations, policies or practices.

01 – Regulation FD Disclosure

Item 7.01 – Regulation FD Disclosure. Presentation slides discussing AngioDynamics and its fiscal second quarter ended November 30, 2023 are furnished herewith as Exhibit 99.2. The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.2) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.

Forward-Looking Statements

Forward-Looking Statements This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects", "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of produ

01 – Financial Statements and Exhibits

Item 9.01 – Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated January 5, 2024. 99.2 Presentation, dated January 5, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANGIODYNAMICS, INC. (Registrant) Date: January 5, 2024 By: /s/ Stephen A. Trowbridge Name Stephen A. Trowbridge Title Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.